A test to find the best drugs for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial uses a special test to help choose which drugs might work best for you if you have metastatic colorectal cancer that has stopped responding to first treatment. The goal is to match you with a more effective next therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and able to give consent.
- You have colorectal cancer that has spread to the liver, belly lining, or lymph nodes and can be biopsied.
- Your first line of treatment has stopped working, and you are about to start a new standard therapy.
- You are in generally good health (able to do daily activities) with adequate blood counts and organ function.
- If you could become pregnant, you must use highly effective birth control or abstain from sex for a period of time.
- You have not used another experimental drug or device in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This study tests whether using the Oncogramme® device to guide the first-line treatment improves care for people with metastatic colorectal (colon/rectum) cancer. If the device helps pick the most suitable standard chemotherapy plan, it could lead to better outcomes than choosing without it.
This trial tests whether adjusting treatment based on a simple blood test (circulating tumor DNA) after two cycles of chemo can be safe and effective for people with advanced colorectal cancer. The goal is to tailor therapy to each person's response.
This trial is testing three different combinations of existing and new drugs for advanced or metastatic colorectal cancer that hasn't improved with standard treatments or has spread to the liver. The goal is to see which combination works best and is safe for patients like you.
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
Hear when a new Metastatic Colorectal Cancer (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.